Leishmaniasis

taxonomy

• phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
  • Plasmodium belongs to phylum Apicomplexa

morphology

• single flagellum
• kinetoplast - aggregation of DNA
• similar to Trypanosoma

epidemiology

• 700,000 - 1 mil. new cases per year

20,000-30,000 deaths per year

life cycle

• parasitize in human macrophage
• promastigote - 10-25 μm
  • with flagellum
  • transform from amastigote inside sandfly midgut
  • proliferate inside midgut
  • introduced into human skin directly from sandfly midgut during sandfly bite
  • phagocytized by macrophage
• amastigote - 2-4 μm
  • transform from promastigote and propagate inside macrophage
  • transform to promastigote inside sandfly midgut
• simpler than Trypanosoma
• vector: sandfly
• host: human, dog, rodent

sand flly

• Phlebotomus spp.
  • Eurasian
• Lutzomya spp.
  • Latin America
• Feed during night

clinical manifestation

visceral leishmania

• most serious
• same as Kala-azar
  • Latin "black fever"
• incubation 3 weeks to >years
• symptoms
  • fever -generally low grade
  • weight loss
  • hepatosplenomegaly - extremely substantial
    • completely subsides rapidly by treatment
  • cough, diarrhea
  • anemia, leukopenia, thrombocytopenia
• many patients are asymptomatic and cured spontaneously
  • cell-mediated immunity
• 50,000-90,000 new cases reported per year 2004-2008
• 202,200-389,100 new cases estimated per year 2004-2008 - underreporting
  • mainly children affected
  • India, Ethiopia, South Sudan, Uganda, Brazil
    • South Asia- decreasing trend towards elimination
    • South Asia- epidemic wave pattern every 15 years
    • East Africa- no decreasing trends
    • East Africa-
    • Latin America-
• L. donovani
  • India, Africa
  • anthroponotic = maintained in human-to-human infection
• L. infantum (formerly L. chagasi was thought separated species)
  • Mediterranean, China, South America
  • dog, cattle is reservoir

diagnosis of visceral leishmania

• suspect for >2 weeks fever+splenomegaly with geographical relation
• detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
  • sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
    • 0.1% of life-threatening hemorrhage by spleen aspiration
• culture in NNN media
• immunochromatographical detection of rk39 antigen
  • dip stick form
  • 97-100% sensitivity in Asia, low in Africa
    • reason unkown, possibly the difference of subspecies
  • cannot distinguish between active or relapse
  • unkown sensitivity in HIV co-infection
• in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
• PCR
• importance of accurate diagnosis
  • clinical features of VL resemble
• DDx
  • chronic malaria
  • schistosomiasis
  • typhoid
  • tuberculosis - splenomegaly is rare unless miliary TB
  • hematological malignancy
• can be verically transmitted - rare
• Treatment
  • to reduce parasite burden
  • to improve complication
  • to help to induce cell-mediated immunity
• Tx in India
  • liposomal AMPH-B
    • +miltefosine
    • +paromomycin
    • +
  • AMPH-B - adherence is diffucult
  • miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
  • drug interactions
• Tx in East Africa
• Tx for L. infantum in Latin America

post kala-azar dermal leishmanisis (PKDL)

• skin manifestation after completion of Tx of visceral leishmaniasis
  • macular type, papular type, nodular type
  • possibly 5-10% of VL patients
  • incidence 4.8/1000 in India
• Leishmania may be detected from skin specimen in some cases
  • skin is contagious
  • reservoir
• diagnosis
  • history of VL
  • rK39
• treatment
  • no good evidence
  • miltefosine for 12 weeks

cutaneous leishmania

• most common
• same as Oriental sore, Chiclero ulcer (in Latin America)
• papule, nodule → ulcer → scar
• basically self-limited
• rarely diffuce or disseminated
• 600,000-1 mil. new cases per year
• Afghanistan, Algeria, Brazil, Colombia, Iran, Syria
  • imported in Texas, US in 2015
• L. tropica, L. mexicana, L. amazonensis and other species >20
• Rhombomys opimus (great gerbil) is primary reservoir

• cutaneous leishmaniasis by L. donovani is reported in Sri Lanka

diagnosis of cutaneous leishmaniasis

• smear of fine needle aspirate or biopsy of skin lesion
• serological test is of no use; low sensitivity and variable specificity

mucocutaneous leishmania

• same as Espundia, white leprosy
• lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
• L. braziliensis, L. panamensis
• Bolivia, Brazil, Peru
• progressive ever without treatment
• secondary bacterial infection

diagnosis of mucocutaneous leishmaniasis

• leishmania is scarce in mucosal lesion
  • strong local immune response
• serology or molecular

emerging novel leishmaniasis

• in Thailand
• L. siamensis, L. martiniquensis

treatment

• pentavalent antimonial
  • meglumine antimoniate
  • sodium stibogluconate
• amphotericin B
  • liposomal amphotericin B
• paromomycin
• pentamidine
• miltefosine

• cryotherapy
  • liquid nitrogen
• thermotherapy
  • 50℃ for 30min.

vaccine

• no human vaccine
• canine vaccine has been rolled out
• "leishmanization" in Uzbeskistan
  • intradermal inoculation of live wild strain of L. major

control

• case detection and treatment for anthroponotic leishmaniasis
• vector control for sandfly-borne leishmaniasis
• destruction of burrows of great gerbil